AusBiotech’s Post

Oh! Look at this! Another one of my favorite panel! ❤️ Private funding: how start-ups using synbio for environnemental applications can raise money from investors? 🤑 That will be a passionating discussion !! 🔥 #deeptech #synbio #climate

The white paper “Biotech Innovation Hubs in Germany – Divided and Conquered?” by the DEEP - Institute for Deep Tech Innovation at ESMT Berlin and the international Boston Consulting Group (BCG) introduces the Biotech Innovation Hub Index (BIHI) to assess and compare the effectiveness of such hubs in Europe and the U.S. The study, which places a special focus on Europe’s largest economy Germany, reveals that European hubs lag behind those in the U.S. except in academic research quality. 👉 Read more: https://lnkd.in/e_pSmrjC #Biotech #biotechinnovation 

Thrilled to join Lord Mayor of Melbourne Sally Capp AO to officially open Jumar Bioincubator, Australia’s newest #biotech incubator. The state-of-the-art facilities, infrastructure and support offered by Jumar create a world-class hub for biotech innovation translation, research commercialisation and talent development, that will help to progress discoveries towards real-world patient treatments.   The official opening was hosted by founding partners WEHI, CSL, and the University of Melbourne, as well as initial investor Breakthrough Victoria and operator Cicada Innovations.   “By nurturing the next wave of biotech entrepreneurs, Jumar Bioincubator is helping to take the most exciting ideas out of research laboratories and into the world, for the benefit of our communities,” says Professor Alan Cowman AC, Acting Director, WEHI. “We need to accelerate the translation of innovative Australian discoveries into the new treatments, diagnostics and devices that can have the greatest impact on global human health – and Jumar is a vital step forward for this.” From mini brains to lab-on-a-chip wearables, the first 16 innovative early-stage ventures that have taken up residency at Jumar are working on a range of health issues across pharmaceuticals, diagnostics, medical devices, bioinformatics and health-related AI. Anne-Laure Puaux Seth Jones #Innovation #BiotechInnovation #AustralianBiotech #ResearchTranslation #BiotechStartups  

Matchmaking between spinouts and investors: At the Nordic Innovation Fair 2024, 20 cases from Aarhus Universitet are looking for their next investment 💡💰 The Nordic Innovation Fair will take place on 23.-24. September in Industriens Hus, Copenhagen, with more than 100 strong commercialisation projects from Denmark and our Nordic neighbours – the vast majority are future or founded spin-outs seeking investments. 20 of the participating spin-outs come from Aarhus University, of which 15 are within the life science area. The remaining cases come from the Greentech & Food and Quantum Tech & Digital areas. Six of the 20 AU spin-outs will be pitching on stage, including Kripthonite Therapeutics, Ardos, SymbioMatch and Aortic Phlex. We hope that a lot of spinouts will get good investments 👏 Read more about the Nordic Innovation Fair here https://lnkd.in/dYJhWcny The Danish universities are organising the Nordic Innovation Fair. Novo Nordisk Foundation is the main sponsor. Morten Holmager Jonas Brandt

Financial opportunity for companies with digital and technical solutions creating impact in the life science industry and/or healthcare. The Life science industry needs to make a shift to facilitate sustainable development while simultaneously healthcare is facing significant challenges. These societal challenges, along with the industry’s transition, require increased digital maturity, more innovations, and greater use of digital tools. Therefore, STUNS Life science offers the program BIO-X Accelerate where companies are given the opportunity to validate their solutions against the life science industry and/or healthcare. The aim is to create IMPACT to facilitate the sustainable development, whether it is through improvements, changes, or conditions, in order to facilitate, simplify, or accelerate the process. Learn more: https://lnkd.in/geyMwccS

📣BIOCAPITAL SUMMIT PANEL PREVIEW📣 "Attracting capital to emerging biotech hubs" As we know, biotech innovation isn’t just about developing groundbreaking science; it is also about finding the capital to make it come to life. It’s an industry where scientific research and progress meet the realities of funding, regulation, and commercialization. This panel brings together venture capitalists, industry leaders, and academics to discuss strategies for attracting biotech capital to an emerging biotech hub, exploring the unique strengths and opportunities within the region to drive innovation and growth in the biotechnology sector. MODERATOR: Julia Monfrini Peev, Managing Partner - PACE Healthcare Capital ⭐ Tim Walbert, Former Chairman, President and Chief Executive Officer, Horizon Therapeutics; Sr. Advisor, Amgen ⭐ Michal Preminger, Regional Head, Johnson & Johnson Innovative Medicine, E. North America ⭐ Stephen Squinto, CIO, J.P. Morgan Life Sciences Private Capital ⭐ Dana Watt, PhD Watt, Partner, Breakout Ventures ⭐ Martin Burke, May and Ving Lee Professor for Chemical Innovation, and Professor of Chemistry, University of Illinois Urbana-Champaign #CBCSummit2024 #Biotech #Chicago #LifeSciences #Networking #Biotechnology

Here are 4 reasons why Switzerland is one of the most innovative locations for #biotech! 🇨🇭 💡 Ecosystem built for innovation 🌍 A European hub 🌐 Biotech clusters fostering innovation 🏦 Strong backing for biotech ventures Learn more in this article about Switzerland's strong biotech ecosystem 🧬👇

The biotech space is constantly evolving, with new medicines, new technologies and new leaders coming into the space. But what hasn’t changed over the past few decades is the main biotech hubs across the US, with Boston & SF still leading the way. These biotech centres are often charazterized by support from academic and research institutions, an infusion of venture capital, number of jobs and government incentives. Where will see the next set of emerging biotech hubs over the next few years? Comment below 👇

“In order to make it easier to bring biotech from the laboratory to factory and then onto the market we will propose a new European Biotech Act in 2025.” In her Strategic Plan for the next 5 years, the President of the European Commission, Ursula von der Leyen, confirmed her determination to strengthen the competitiveness of the biotechnology sector in Europe. The European Biotech Act is a strong commitment by the Commission and the Member States to defend our technological leadership and ensure that our ecosystem is not held back in its promising development. Belgium's priorities for the Biotech Act are clear: to simplify European regulations to speed up the time-to-market for innovative products, to ensure the financing of innovation and production projects through fund-raising capacities comparable to those in the United States or Asia, and finally, to encourage Europe-wide collaboration around facilitating tools such as incubators, bioclusters, digitisation of production tools, etc. Over the last few decades, Belgium has forged an internationally recognised reputation for excellence in the life sciences sector. The Biotech Act will need to define a framework that will enable it to maintain this excellence. Tineke Van hooland Pio PETER Jerome Van Biervliet Luc Debruyne Marc Dechamps Skander Nasra Thomas Van Cangh EuropaBio - the European Association for Bioindustries Claire Skentelbery Dr Anne-Gaelle Collot Adrien Samson José P. bio.be/essenscia

Good initiative. May I ask : How will the European Biotech Act specifically address the challenges faced by small biotech companies, particularly those focused on fighting antimicrobial resistance (AMR) such as Immunochem? Don't get me wrong, it is good that we see "determination" from the politicians, but their timelines is on the yearS scale and we count the days in our activities. Funding is one of the most important priority and challenge especially when you compare to US or China possibilities (Hello iTeos Therapeutics). #AMR #FUNDING #INNOVATE